Pharmacologic management of chronic reno-cardiac syndrome.
Chronic kidney disease (CKD) significantly increases cardiovascular morbidity and mortality. CKD remains an under-represented population in cardiovascular clinical trials, and cardiovascular disease is an under-treated entity in CKD. Traditional cardiovascular risk factors in conjunction with uremia-related complications often progress to myocardial dysfunction. Such uremic cardiomyopathy leads to over-activation of neurohormonal pathways with detrimental effects. Management of the reno-cardiac syndrome (RCS) requires the targeting of these multiple facets. In this article we discuss the relevant pathophysiology of RCS, and present the clinical data related to its management.
Published In/Presented At
Hawwa, N., Schreiber, M. J., Jr, & Tang, W. H. (2013). Pharmacologic management of chronic reno-cardiac syndrome. Current heart failure reports, 10(1), 54–62. https://doi.org/10.1007/s11897-012-0122-8
Medicine and Health Sciences
Department of Medicine, Cardiology Division